CO36 Network Meta-Analysis (NMA) to Assess Comparative Efficacy of Lenvatinib Plus Pembrolizumab Compared with Other First-Line Treatments for Management of Advanced Renal Cell Carcinoma (ARCC)

Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.134
https://www.valueinhealthjournal.com/article/S1098-3015(22)00335-7/fulltext
Section Title :
Section Order : 10110
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00335-7&doi=10.1016/j.jval.2022.04.134
HEOR Topics :
Tags :
Regions :